Intrinsic4D Inc.
TSX VENTURE : IFD

December 14, 2015 10:51 ET

Intrinsic4D Announces Initial Results of Clinical Testing for the Non-Invasive Functional Assessment of Coronary Artery Disease

TORONTO, ONTARIO--(Marketwired - Dec. 14, 2015) - Intrinsic4D Inc. ("Intrinsic4D") (TSX VENTURE:IFD) announces positive results from its first study comparing Intrinsic4D's Stenosis Severity Mapping ("SSM") Cardio application to invasive data. Intrinsic recently completed the initial phase of the study that performed a non-invasive functional analysis of coronary arteries that exhibited an array of conditions ranging from healthy to diseased arteries.

In collaboration with a leading U.S. heart hospital, Intrinsic4D's non-invasive computation of blood flow restriction using a computed tomography (CT) scan was blindly compared to previously performed invasive cardiac tests on the same patients, that included fractional flow reserve and cardiac catheterizations.

Intrinsic4D's non-invasive results achieved a 93% (14/15) correlation with the same patient's invasive studies. The outcome is a key step towards validating Intrinsic4D's SSM Cardio application.

"I am pleased with the remarkable correlation of the SSM Cardio solution to the invasive data. The ability to non-invasively quantify the restriction of blood flow associated with a risky lesion can yield tremendous benefits for cardiologists including the reduction of unnecessary cardiac catheterizations and improved patient care," said Neil Bilolikar, attending cardiologist at William Beaumont hospital in Royal Oak, Michigan.

Intrinsic4D's next step will be to scale this study to a larger patient population in order to demonstrate repeatability of this groundbreaking solution.

"We will continue to push the limits of medicine and technology, with the goal of improving patient care while enabling significant cost savings for health care providers," said Jorey Chernett, CEO of Intrinsic4D.

About Intrinsic4D Inc.

Intrinsic4D, through its Authentic brand, is the developer of the patented and FDA- cleared transformative software-as-a-service medical platform servicing the medical-legal industry. Through its patented and disruptive Stenosis Severity Mapping (SSM) Cardio solution, it aims to reduce the $13 billion of unnecessary cardiac catheterizations performed annually, which are attributed to false positive reads of diagnostic tests for evaluating coronary artery disease.

Disclaimer for Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable securities laws. Forward-looking information may relate to the Corporation's future outlook and anticipated events or results. Particularly, statements regarding future results, performance, achievements and prospects or opportunities for the Corporation are forward looking statements. Some of the specific forward looking statements in this press release include, but are not limited to, statements with respect to the potential for the SSM Cardio technology resulting in improved patient care while enabling significant cost savings for health care providers. Although the forward-looking statements contained in this press release are based upon assumptions that management of the Corporation believes are reasonable based on information currently available to management, there can be no assurance that actual results will be consistent with these forward-looking statements. Forward-looking statements necessarily involve known and unknown risks and uncertainties, many of which are beyond the Corporation's control, which may cause actual results to differ materially from those expressed or implied by such forward-looking statements. The forward-looking statements made in this press release relate only to events or information as of the date hereof. Except as required by applicable law, the Corporation undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Contact Information